Porownywarka

Melanotan II vs Ipamorelin side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

Melanotan IIIpamorelin

Udostępnij porównanie peptydów

Wlasciwosc	Melanotan II	Ipamorelin
Kategoria	Zdrowie seksualne	Hormon wzrostu
Znany tez jako	MT-II, MT2, Melanotan 2	IPAM, NNC 26-0161
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Not approved; research reportedly discontinued due to side effects. Source also lists FDA Category 2 restricted status tied to melanoma risk and other safety concerns. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Tanning, libido enhancement, erectile function	Anti-aging, muscle building, sleep quality, recovery
Jak dziala	Melanotan II is reported as a broad melanocortin receptor agonist rather than a receptor-selective compound. The source names MC1, MC3, MC4, and MC5 as targets. MC1 signaling in melanocytes is tied to melanin production, while MC4 signaling in the central nervous system is linked to sexual arousal and desire pathways. The broad receptor profile is also presented as a reason for a wider adverse-effect profile.	Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response.
Typowe dawkowanie	250-500 mcg daily (loading), then 500-1,000 mcg weekly (maintenance) · Daily during loading (1-2 weeks), then weekly maintenance · Loading 1-2 weeks, then maintenance · Subcutaneous injection	200-300 mcg 2-3x daily · 2-3x daily
Dawkowanie z badań	250-500 mcg initially · Loading phase 2-3 weeks, then maintenance · Subcutaneous injection	100-300 mcg per injection · 8-12 weeks typical · Subcutaneous injection
Typowy czas trwania	Loading phase 2-3 weeks, then maintenance	8-12 weeks typical
Podanie	Subcutaneous injection	Subcutaneous injection
Timing	Evening or before sun exposure With or without food	Before bed or morning, fasted Fasted timing reported
Poziom dowodów	Badawcze	Badania kliniczne
Mozliwe skutki uboczne	Nausea (Reported as common, especially initially.) Facial flushing Fatigue +6 więcej Spontaneous penile erections Darkening of skin and moles (Source highlights mole changes and pigmentation concerns.) Priapism (Source flags this as an emergency-risk adverse event.) Association with melanoma risk (Source links restricted status and dermatology cautions to melanoma risk concerns.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Legal restriction caution (Source reports illegality in the US, UK, and Australia; this regulatory claim needs admin review.)	Generally well tolerated (Reported by the source as a general tolerability statement, not a guarantee of safety.) Injection-site reactions Headache +6 więcej Nausea Increased appetite Water retention Temporary joint stiffness (Source describes joint stiffness as temporary.) No significant cortisol or prolactin elevation reported (Source presents this as a selectivity-related observation.) Contraindicated with active malignancy (Listed by the source as a contraindication.)
Podsumowanie researchu	The supplied research summary describes narrow older human evidence for erectile-function outcomes. In men with organic erectile dysfunction, the source reports subjectively described erections after 12 of 19 Melanotan II injections compared with 1 of 21 placebo doses, plus longer rigidity periods and greater sexual interest; nausea and yawning were frequent. The source connects this effect profile to later bremelanotide development. For tanning, the same source emphasizes lack of large safety trials and dermatology concerns including changing moles, melanoma reports, uneven or lasting pigmentation changes, nausea, and risks from unregulated injected material.	The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes.
Referencje	WikipediaMelanotan II PubMedPubMed record 11018622 +1 więcej DermNetMelanotan II	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Melanotan II

Ipamorelin

Kategoria

Zdrowie seksualne

Hormon wzrostu

Znany tez jako

MT-II, MT2, Melanotan 2

IPAM, NNC 26-0161

Zatwierdzony przez FDA

Nie

Status kliniczny

Not approved; research reportedly discontinued due to side effects. Source also lists FDA Category 2 restricted status tied to melanoma risk and other safety concerns.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Tanning, libido enhancement, erectile function

Anti-aging, muscle building, sleep quality, recovery

Jak dziala

Melanotan II is reported as a broad melanocortin receptor agonist rather than a receptor-selective compound. The source names MC1, MC3, MC4, and MC5 as targets. MC1 signaling in melanocytes is tied to melanin production, while MC4 signaling in the central nervous system is linked to sexual arousal and desire pathways. The broad receptor profile is also presented as a reason for a wider adverse-effect profile.

Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response.

Typowe dawkowanie

250-500 mcg daily (loading), then 500-1,000 mcg weekly (maintenance) · Daily during loading (1-2 weeks), then weekly maintenance · Loading 1-2 weeks, then maintenance · Subcutaneous injection

200-300 mcg 2-3x daily · 2-3x daily

Dawkowanie z badań

250-500 mcg initially · Loading phase 2-3 weeks, then maintenance · Subcutaneous injection

100-300 mcg per injection · 8-12 weeks typical · Subcutaneous injection

Typowy czas trwania

Loading phase 2-3 weeks, then maintenance

8-12 weeks typical

Podanie

Subcutaneous injection

Timing

Evening or before sun exposure

With or without food

Before bed or morning, fasted

Fasted timing reported

Poziom dowodów

Badawcze

Badania kliniczne

Mozliwe skutki uboczne

Nausea (Reported as common, especially initially.)
Facial flushing
Fatigue

+6 więcej

Spontaneous penile erections
Darkening of skin and moles (Source highlights mole changes and pigmentation concerns.)
Priapism (Source flags this as an emergency-risk adverse event.)
Association with melanoma risk (Source links restricted status and dermatology cautions to melanoma risk concerns.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Legal restriction caution (Source reports illegality in the US, UK, and Australia; this regulatory claim needs admin review.)

Generally well tolerated (Reported by the source as a general tolerability statement, not a guarantee of safety.)
Injection-site reactions
Headache

+6 więcej

Nausea
Increased appetite
Water retention
Temporary joint stiffness (Source describes joint stiffness as temporary.)
No significant cortisol or prolactin elevation reported (Source presents this as a selectivity-related observation.)
Contraindicated with active malignancy (Listed by the source as a contraindication.)

Podsumowanie researchu

The supplied research summary describes narrow older human evidence for erectile-function outcomes. In men with organic erectile dysfunction, the source reports subjectively described erections after 12 of 19 Melanotan II injections compared with 1 of 21 placebo doses, plus longer rigidity periods and greater sexual interest; nausea and yawning were frequent. The source connects this effect profile to later bremelanotide development. For tanning, the same source emphasizes lack of large safety trials and dermatology concerns including changing moles, melanoma reports, uneven or lasting pigmentation changes, nausea, and risks from unregulated injected material.

The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes.

Referencje

WikipediaMelanotan II PubMedPubMed record 11018622

+1 więcej

+1 więcej

Pełny profil